Marathon Pharmaceuticals

PTC Therapeutics to acquire Emflaza for Duchenne muscular dystrophy

Thursday, March 16, 2017

PTC Therapeutics has entered into an asset purchase agreement with Marathon Pharmaceuticals to acquire all rights to Emflaza (deflazacort). Emflaza is the first treatment approved in the U.S. for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation. DMD is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death due to heart and respiratory failure. Emflaza aligns with PTC’s mission to bring therapies to patients who have rare diseases with limited or no treatment options.

[Read More]

FDA approves EMFLAZA for Duchenne muscular dystrophy

Monday, February 13, 2017

Marathon Pharmaceuticals, a U.S. research-based biopharmaceutical company focused solely on the development of new treatments for rare diseases, has announced that the FDA granted approval of EMFLAZA (deflazacort) for the treatment of Duchenne muscular dystrophy in patients 5 years and older. Duchenne, a severe form of muscular dystrophy, is a rare disease and fatal genetic disorder that affects about 15,000 people in the U.S.

[Read More]

FDA accepts grants Marathon’s Duchenne drug Deflazacort priority review

Thursday, August 11, 2016

Marathon Pharmaceuticals, a biopharmaceutical company developing treatments for rare diseases, has announced the New Drug Applications (NDA) for the investigational drug deflazacort have been accepted for filing and granted Priority Review by the FDA. The NDAs (one for immediate-release tablet formulations and one for an oral suspension formulation) request approval for deflazacort for the treatment of patients with Duchenne muscular dystrophy (DMD), the most common and most severe form of muscular dystrophy.

[Read More]